The Influence of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Renal Function in Patients Undergoing Non-emergent Coronary Angiography

Soroka University Medical Center100 enrolled

Overview

The aim of the current study is to evaluate prospectively whether concomitant administration of RAAS blockers (namely ACE-I and ARBs') influence the change in estimated GFR (eGFR) after administration of contrast media in patients undergoing non-emergent coronary angiography.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

DIAGNOSTIC

Masking

NONE

Enrollment

100

Conditions

Blood Pressure

Interventions

stop ace-i/arb 24 h before procedure and restarted 24 hours after the procedureDRUG

ACE/ARB stopped 24 hours prior to the procedure and restarted 24 hours after the procedure

ACE/ARB stopped 24 hours before procedure and start immediately afterDRUG

ACE/ARB stopped 24 hours prior to the procedure and restarted immediately after the procedure

Eligibility

Sex: ALLMin age: 18 YearsMax age: 100 Years

Medical Language ↔ Plain English

Inclusion Criteria: * 1\. Age\>18 years * 2\. Subjects on chronic therapy with ACE-I and/or ARBs' (confirmed by electronic records in their medical file) * 3\. Subjects planned to undergo non-emergent coronary angiography. * 4\. Signed informed consent Exclusion Criteria: * 1\. eGFR\<30 ml/min at baseline * 2\. Chronic utilization of NSAIDS and Cox-2 selective inhibitors * 3\. Chronic treatment with mineralocorticosteroid receptor blocker * 4\. Systolic blood pressure\<90 mmHg * 5\. Planned staged (repeated) procedure within 48 hours * 6\. Administration of contrast within 14 days prior to the enrollment * 7\. contraindication to stop ACE-I or ARB'S

Locations (1)

Talya Wolak

Bear Sheva, Israel

Outcomes

Primary Outcomes

Change in eGFR from baseline to 48 hours following the exposure to the contrast.

Time frame: 48 hours after exposure to the contrast

Secondary Outcomes

1. Rate of eGFR decrease>25% from the baseline, 2. Length of hospitalization,

Time frame: 48-72 hours after exposure to contrast

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.